The bill amends the Uniform Controlled Dangerous Substances Act in Oklahoma by updating the definitions and classifications of various substances, particularly focusing on cannabinoids and their derivatives. It modifies the definition of "marijuana" to include "Cannabis" and expands its description to cover tetrahydrocannabinols and synthetic equivalents, while excluding certain parts of the plant like mature stalks and seeds. The bill introduces new substances to Schedule I and Schedule III, including Dronabinol, and makes specific deletions and modifications in the classification of existing substances, such as replacing 11. with 12. for Ketamine. It also clarifies that any prescription drug approved by the FDA that is designated or rescheduled as a controlled substance will be regulated according to federal law. Additionally, the bill outlines definitions for terms related to controlled substances, such as "acute pain," "chronic pain," and "drug paraphernalia," aiming to enhance the regulatory framework surrounding their use and distribution. It emphasizes the importance of patient-provider agreements in opioid therapy and establishes exceptions for certain industrial uses of specific substances, allowing for exemptions from Schedule I classification under certain conditions. The bill is set to take effect on November 1, 2026, providing a transition period for stakeholders to adapt to the new regulations.